COVID-19

Keeping ahead of flu season and preventing illness through immunizations is critical to reducing an already-strained health care system.

Here's a roundup of this week's coronavirus-related news.

The phase 2/3 trials will evaluate remdesivir (Gilead) in pediatric patients, from newborns to adolescents, who have contracted severe COVID-19 symptoms.

New legislation authorizes licensed New York pharmacists to administer a vaccine for coronavirus disease 2019 (COVID-19) when it becomes available.

In a video interview with Drug Topics®, Robert Brunault, PharmD, a clinical pharmacy specialist in hematology and oncology at Rhode Island Hospital and the Lifespan Cancer Institute, discussed how pharmacies are protecting patients with cancer during the novel coronavirus disease 2019 (COVID-19) pandemic.

The CDC released an updated vaccination guidance on administering routine vaccinations amid the coronavirus disease 2019 (COVID-19) pandemic.

Via a new web platform, pharmacy technicians are sharing their personal challenges during the coronavirus disease 2019 (COVID-19) pandemic.

The FDA updated its fact sheet on the co-administration of remdesivir with chloroquine phosphate or hydroxychloroquine.

Armand Balboni, MD, PhD, chief executive officer of Appili Therapeutics, discusses the potential for favipiravir, an antiviral medication, for treating COVID-19 in certain populations.

Since the emergency use authorization was granted, new data on heart risks associated with hydroxychloroquine and chloroquine have been revealed.

Armand Balboni, MD, PhD, chief executive officer of Appili Therapeutics, discusses the potential for favipiravir, an antiviral medication, for treating COVID-19 in certain populations.

Julie Ann Justo, PharmD, infectious diseases clinical pharmacist and assistant professor at the University of South Carolina College of Pharmacy, discusses the treatment potential for remdesivir for SARS-CoV-2, as well as distribution strategies for the drug.

Carla Cox, PhD, registered dietician and certified diabetes educator, discusses key information about COVID-19 that individuals with diabetes should know.

In an interview with Drug Topics®, Richard Scholz, chief strategy officer of ERxDirect, explained the prominence of telemedicine during the COVID-19 pandemic and the lasting implications of new technologies during unprecedented times.

In part 2 of our interview, Mike Johnston, founder and chief executive officer of the National Pharmacy Technician Association (NPTA), discussed the results of their recent survey, which found that many pharmacists and pharmacy technicians feel unsafe from COVID-19 at their workplaces.

Mike Johnston, founder and chief executive officer of the National Pharmacy Technician Association (NPTA), joined Drug Topics® to discuss their recent survey that pinpointed where pharmacists are feeling most unprotected during the pandemic.

In part 2 of our interview, Devin English, assistant professor at Rutgers School of Health, joined Drug Topics® to discuss how COVID-19 is disproportionately affecting minorities.

Devin English, assistant professor at Rutgers School of Health, joined Drug Topics® to discuss how COVID-19 is disproportionately affecting minorities, the history that explains this trend, and the issues that will remain after the pandemic ends.